Merrill keeps Amylin at sell

Amylin Pharmaceuticals Inc. was maintained at a sell by Merrill Lynch analyst Thomas McGahren on news that fourth-quarter 2005 Byetta sales of $49 million beat the analyst's estimate of $45 million. Merrill is raising its 2006 Byetta sales estimate to $285 million from $281 million. Shares of the San Diego pharmaceutical company were up 92 cents, or 2.08%, at $45.25 on volume of 2,664,537 shares versus the three-month running average of 2,104,310 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.